<DOC>
	<DOCNO>NCT02604212</DOCNO>
	<brief_summary>Patients HBeAG positive , chronic Hepatitis B Virus ( HBV ) infection receive either ARC-520 placebo combination entecavir tenofovir , evaluate safety efficacy .</brief_summary>
	<brief_title>A Multi-dose Study ARC-520 Patients With Hepatitis B ' e ' Antigen ( HBeAg ) Positive , Chronic HBV Infection</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled , multi-dose study ARC-520 combination entecavir tenofovir administer patient HBeAg positive immune active chronic HBV infection Eligible patient sign Ethics Committee - approve informed consent , enrol receive ARC-520 placebo combination entecavir tenofovir . The study enroll total 90 eligible chronic HBV infect patient . Patients undergo following evaluation regular interval study : medical history , physical examination , vital sign measurement ( blood pressure , heart rate , respiratory rate temperature ) , weight , adverse event assessment ( AEs ) , 12 lead ECGs , liver fibrosis testing , concomitant medication assessment , blood sample collection hematology , coagulation , chemistry , lactate , Pharmacokinetic ( PK ) measure ( subset patient ) , exploratory Pharmacodynamic ( PD ) measure , urinalysis , HBV serology , Follicle Stimulating Hormone ( FSH ) test ( post-menopausal female ) pregnancy test female childbearing potential . Clinically significant change include AEs follow resolution , condition stabilizes , event otherwise explain , patient lose follow-up . For patient duration study approximately 33 week screen Day 169 follow-up visit . For patient enrol plan extension study , total duration study approximately 25 week screen Day 113 end study visit .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>Male female , 18 75 year age . Written informed consent . No clinically significant abnormality screening/predose 12lead ECG assessment . No new abnormal find clinical relevance screen evaluation . Diagnosis HBeAg positive , immune active , chronic HBV infection . &gt; 2months continuous treatment daily , oral entecavir tenofovir . Willingness continue take entecavir tenofovir throughout study . Must use 2 effective method contraception ( double barrier contraception hormonal contraceptive along barrier contraceptive ) ( male female partner ) . Pregnant lactate Acute sign hepatitis/other infection within 4 week screen . Antiviral therapy entecavir tenofovir within 3 month screen . Prior treatment interferon last 3 year . Use within last 6 month anticipate requirement anticoagulant , corticosteroid , immunomodulators , immunosuppressant . Use prescription medication within 14 day prior treatment administration except : topical product without systemic absorption , statin ( except rosuvastatin ) , hypertension medication , hormonal contraceptive . Depot injection implant drug within 3 month prior treatment administration , except injectable/implantable birth control . Diagnosis diabetes mellitus . History autoimmune disease especially autoimmune hepatitis . Human immunodeficiency virus ( HIV ) infection . Seropositive Hepatitis C Virus ( HCV ) , and/or history delta virus hepatitis . Hypertension define blood pressure &gt; 150/100 mmHg . History cardiac rhythm disturbance . Family history congenital long QT syndrome , Brugada syndrome unexplained sudden cardiac death . Symptomatic heart failure , unstable angina , myocardial infarction , severe cardiovascular disease within 6 month prior study entry . History malignancy except adequately treat basal cell carcinoma , squamous cell skin cancer , superficial bladder tumor , situ cervical cancer . Has major surgery within 3 month screen . History alcohol and/or drug abuse &lt; 12 month screen . Regular us alcohol within 6 month prior screen ( ie , 14 unit alcohol per week ) . Evidence severe systemic acute inflammation , sepsis , hemolysis . Diagnosed significant psychiatric disorder . Use recreational drug , marijuana , within 3 month prior screen . Use drug cocaine , phencyclidine ( PCP ) , methamphetamine , within 1 year prior screen . History allergy bee sting . Use investigational agent device within 30 day prior plan study dose current participation investigational study . Clinically significant history presence gastrointestinal pathology , unresolved gastrointestinal symptom , liver kidney disease . Presence cholangitis , cholecystitis , cholestasis , duct obstruction . Clinically significant history presence poorly controlled/uncontrolled systemic disease . History fever within 2 week screen . Immunized live attenuate vaccine within 7 day prior dose plan vaccination ( exclude flu vaccine injection ) . Presence medical psychiatric condition social situation impact compliance result additional safety risk . Participated excessive exercise/physical activity within 7 day screen planned trial . History coagulopathy/stroke within past 6 month , and/or concurrent anticoagulant medication ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>